Value202220232024TTMSelling/general/admin expenses73.36 M70.45 M61.51 M62.27 MResearch & development208.6 M143.62 M151.91 M142.83 MOperating income130.53 M138.05 M137.11 M70.61 MNon-Operating Income, Total1.11 M894 K558 K921 KInterest expense, net of interest capitalized————Non-Operating Income, excl. Interest Expenses1.07 M603 K340 K727 KUnusual income/expense42 K291 K218 K194 KPretax income135.23 M119.24 M116.61 M60.33 MEquity in earnings————Taxes10.89 M568 K6.08 M7.73 MNon-controlling/minority interest————After tax other income/expense————Net income before discontinued operations124.34 M118.67 M122.69 M68.06 MDiscontinued operations————Net income124.34 M118.67 M122.69 M68.06 MDilution adjustment————Preferred dividends————Diluted net income available to common stockholders124.11 M118.67 M122.56 M67.95 MBasic earnings per share (Basic EPS)1.91-1.72-1.62-0.85Diluted earnings per share (Diluted EPS)1.9-1.72-1.62-0.85Average basic shares outstanding65.19 M68.86 M75.85 M302.12 MDiluted shares outstanding65.25 M68.86 M75.88 M304.26 MEBITDA————EBIT————Cost of revenue————Other cost of goods sold————Depreciation & amortization (cash flow)7.24 M10.16 M8.68 M16.98 M
Zymeworks Inc
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics.